Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 14.11 as of Friday, July 31, 2026.
Forward PE Ratio (14.11) = Close Price ($46.73) / Consensus Forward EPS ($3.31)
FORWARD PE RATIO
14.11
SECTOR MEDIAN · HEALTHCARE
19.05
median of 68 covered companies
CURRENT VS SECTOR MEDIAN
-25.95%
vs the sector median at left
Boston Scientific Corporation
Market Cap
$69.46B
Forward PE Ratio
14.11
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Boston Scientific Corporation (BSX) | $69.46B | 14.11 |
| Cigna Corporation (CI)vs › | $73.82B | 9.45 |
| Cencora, Inc. (COR)vs › | $60.57B | 17.51 |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $78.57B | 14.62 |
| Becton, Dickinson and Company (BDX)vs › | $60.00B | 13.13 |
| Elevance Health Inc. (ELV)vs › | $81.51B | 13.85 |
| Cardinal Health, Inc. (CAH)vs › | $53.87B | 21.35 |
| HCA Healthcare, Inc. (HCA)vs › | $87.16B | 13.38 |
| Edwards Lifesciences Corporation (EW)vs › | $49.56B | 28.96 |
| IDEXX Laboratories, Inc. (IDXX)vs › | $44.10B | 38.17 |
Trailing P/E
19.0
reported TTM EPS
Forward P/E
14.1
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $3.31 implies +34.6% EPS growth vs the reported trailing $2.46.
At today's $46.73 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $3.31 | $3.26 – $3.35 | 14 | 14.1x |
| 2027-12-31 | $3.45 | $3.37 – $3.56 | 16 | 13.5x |
| 2028-12-31 | $3.78 | $3.47 – $4.37 | 7 | 12.4x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
